Rezlidhia (olutasidenib capsules) — Cigna
Acute Myeloid Leukemia (relapsed or refractory) with a susceptible IDH1 mutation
Initial criteria
- Patient age ≥ 18 years
- Patient has relapsed or refractory disease
- Patient has isocitrate dehydrogenase-1 (IDH1) mutation positive disease as detected by an approved test
Approval duration
1 year